Zoetis (ZTS) has experienced a significant
22% decline in share price which has caught the attention of multiple investors. However, several establishments, including
Truist Financial Corp and
111 Capital have increased their holdings. <>At the same time, Zoetis' market valuation has weathered criticism, being dubbed as pricey despite significant advancements such as positive opinions from the
Committee for Medicinal Products for Veterinary Use (CVMP) for
Portela, and the
FDA's conditional approval for a cattle treatment. These advancements have supported the perception of Zoetis as a
strong growth stock. <>The company has received separate approvals from the European Medicines Agency (EMA) for innovative livestock parasite treatments and the breakthrough cat osteoarthritis therapy,
Portela. <>Notably, extensive buy and sell transactions of ZTS shares from various institutions were reported with some reducing their stakes due to its high valuation. <>Despite this, Zoetis' strong Q2 performance, reporting
$2.5 billion in revenue, has led to an upward revision of its full-year outlook, driven by strong pet care demand. The company's key franchises remain resilient amid market competition, and it continues to invest in animal health innovation.
Zoetis ZTS News Analytics from Fri, 30 May 2025 07:00:00 GMT to Sat, 04 Oct 2025 10:24:42 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -4
